Latest Period
n/a
Security Snapshot
BiomX Inc. - Common Stock, par value $0.0001 per share (PHGE) Institutional Ownership
CUSIP: 09090D103
13F Institutional Holders and Ownership History from Q3 2019 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- PHGE on NYSE
- Shares outstanding
- 1,588,808
Security identity
2 facts
Issuer context
1 fact
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- PHGE - BiomX Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 09090D103.
- Latest finished 13F holder period is not available.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 2 to 0 between Q3 2025 and Q4 2025.
- Reported value moved from $50,938 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
09090D103
Latest holder period
n/a
13F holders
13D/G owners
5
CIK / CUSIP context first
PHGE full holder history
BiomX Inc. SEC filings
BiomX Inc. company facts
BiomX Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09090D103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
PHGE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cystic Fibrosis Foundation | 10% | -50% | $349,175 | -$887,608 | 2,494,110 | -39% | Cystic Fibrosis Foundation | 27 Feb 2025 |
| T3 Defense Inc. | 20% | 1,600,000 | Menachem Shalom | 10 Apr 2026 | ||||
| Flynn James E | 10% | 0% | 989,056 | -94% | Deerfield Management Company, L.P. | 15 Apr 2026 | ||
| OrbiMed Israel BioFund GP Limited Partnership | 1% | 276,150 | ORBIMED ISRAEL GP LTD. | 18 Jun 2025 | ||||
| Centaurus Investments Ltd | 5.2% | 82,618 | Rodney Hodges | 31 Mar 2026 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Latest
n/a
Rows shown
1-25 of 26
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$50,938 | 0 | |
| 2025 Q3 | 97,025 | $50,938 | $0.52 | 2 | |
| 2025 Q2 | 97,025 | $42,693 | $0.45 | 2 | |
| 2025 Q1 | 97,025 | $53,916 | +$88 | $0.55 | 2 |
| 2024 Q4 | 96,866 | $70,722 | -$180,485 | $0.73 | 1 |
| 2024 Q3 | 300,942 | $306,960 | -$9,565,291 | $1.02 | 2 |
| 2024 Q2 | 23,249,529 | $7,814,136 | +$3,181,319 | $0.34 | 10 |
| 2024 Q1 | 13,770,839 | $6,196,607 | +$2,595,251 | $0.45 | 9 |
| 2023 Q4 | 8,090,280 | $2,264,622 | -$123,934 | $0.28 | 13 |
| 2023 Q3 | 7,452,452 | $2,623,356 | -$89,858 | $0.35 | 10 |
| 2023 Q2 | 7,707,696 | $2,773,941 | +$508,054 | $0.36 | 9 |
| 2023 Q1 | 6,330,423 | $1,930,752 | +$60,640 | $0.30 | 12 |
| 2022 Q4 | 6,162,512 | $1,150,412 | -$38,941 | $0.19 | 13 |
| 2022 Q3 | 6,160,749 | $2,095,000 | -$5,123 | $0.34 | 14 |
| 2022 Q2 | 6,178,650 | $4,511,000 | -$860,141 | $0.73 | 10 |
| 2022 Q1 | 6,615,338 | $12,767,000 | +$118,120 | $1.93 | 12 |
| 2021 Q4 | 6,557,269 | $10,492,000 | -$754,297 | $1.60 | 12 |
| 2021 Q3 | 6,951,985 | $21,271,508 | +$2,591,956 | $3.06 | 17 |
| 2021 Q2 | 6,092,788 | $33,266,828 | -$586,998 | $5.46 | 13 |
| 2021 Q1 | 6,181,431 | $44,013,000 | -$199,957 | $7.12 | 13 |
| 2020 Q4 | 6,275,013 | $40,034,000 | +$240,907 | $6.38 | 9 |
| 2020 Q3 | 6,223,539 | $39,457,000 | +$654,975 | $6.34 | 9 |
| 2020 Q2 | 6,122,733 | $33,795,000 | +$408,937 | $5.52 | 12 |
| 2020 Q1 | 6,035,721 | $42,249,000 | +$6,038,699 | $7.00 | 10 |
| 2019 Q4 | 5,158,604 | $49,961,000 | +$28,283,000 | $9.68 | 7 |